PL3820446T3 - Kompozycje farmaceutyczne zawierające rpl554 w hfa-134a do podawania przez inhalację - Google Patents

Kompozycje farmaceutyczne zawierające rpl554 w hfa-134a do podawania przez inhalację

Info

Publication number
PL3820446T3
PL3820446T3 PL19790718T PL19790718T PL3820446T3 PL 3820446 T3 PL3820446 T3 PL 3820446T3 PL 19790718 T PL19790718 T PL 19790718T PL 19790718 T PL19790718 T PL 19790718T PL 3820446 T3 PL3820446 T3 PL 3820446T3
Authority
PL
Poland
Prior art keywords
hfa
inhalation
administration
pharmaceutical compositions
compositions containing
Prior art date
Application number
PL19790718T
Other languages
English (en)
Inventor
Peter Lionel Spargo
Phillip A HAYWOOD
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of PL3820446T3 publication Critical patent/PL3820446T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19790718T 2018-10-09 2019-10-09 Kompozycje farmaceutyczne zawierające rpl554 w hfa-134a do podawania przez inhalację PL3820446T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
EP19790718.1A EP3820446B1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (1)

Publication Number Publication Date
PL3820446T3 true PL3820446T3 (pl) 2022-03-14

Family

ID=64394831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19790718T PL3820446T3 (pl) 2018-10-09 2019-10-09 Kompozycje farmaceutyczne zawierające rpl554 w hfa-134a do podawania przez inhalację

Country Status (27)

Country Link
US (2) US20210379053A1 (pl)
EP (2) EP3960157A1 (pl)
JP (2) JP7578587B2 (pl)
KR (1) KR102960903B1 (pl)
CN (1) CN112912064B (pl)
AU (1) AU2019358585B2 (pl)
BR (1) BR112021006712A2 (pl)
CA (1) CA3113167A1 (pl)
CY (1) CY1124943T1 (pl)
DK (1) DK3820446T3 (pl)
ES (1) ES2899744T3 (pl)
GB (1) GB2578093B (pl)
HR (1) HRP20220053T1 (pl)
HU (1) HUE057780T2 (pl)
IL (1) IL282032B2 (pl)
LT (1) LT3820446T (pl)
MX (2) MX2021003599A (pl)
MY (1) MY207302A (pl)
PH (1) PH12021550767A1 (pl)
PL (1) PL3820446T3 (pl)
PT (1) PT3820446T (pl)
RS (1) RS62775B1 (pl)
SG (1) SG11202102567UA (pl)
SI (1) SI3820446T1 (pl)
SM (1) SMT202200044T1 (pl)
WO (1) WO2020074894A1 (pl)
ZA (1) ZA202102039B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
SI2603509T1 (sl) * 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
ES2773142T3 (es) * 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
EP3820446B1 (en) 2021-11-03
US20210379053A1 (en) 2021-12-09
AU2019358585B2 (en) 2025-01-16
GB2578093A (en) 2020-04-22
CN112912064A (zh) 2021-06-04
JP2024113096A (ja) 2024-08-21
SMT202200044T1 (it) 2022-05-12
BR112021006712A2 (pt) 2021-07-27
PT3820446T (pt) 2021-12-03
WO2020074894A1 (en) 2020-04-16
SI3820446T1 (sl) 2022-01-31
CY1124943T1 (el) 2023-01-05
CA3113167A1 (en) 2020-04-16
KR20210073532A (ko) 2021-06-18
IL282032B1 (en) 2026-01-01
IL282032A (en) 2021-05-31
DK3820446T3 (da) 2021-12-06
ZA202102039B (en) 2022-08-31
ES2899744T3 (es) 2022-03-14
JP7578587B2 (ja) 2024-11-06
GB201816447D0 (en) 2018-11-28
US20250049781A1 (en) 2025-02-13
EP3960157A1 (en) 2022-03-02
GB2578093B (en) 2020-11-18
MY207302A (en) 2025-02-15
RS62775B1 (sr) 2022-01-31
MX2024001499A (es) 2024-02-27
EP3820446A1 (en) 2021-05-19
IL282032B2 (en) 2026-05-01
PH12021550767A1 (en) 2021-10-04
SG11202102567UA (en) 2021-04-29
AU2019358585A1 (en) 2021-04-15
CN112912064B (zh) 2025-02-14
HUE057780T2 (hu) 2022-06-28
JP2022513566A (ja) 2022-02-09
JP7836853B2 (ja) 2026-03-27
KR102960903B1 (ko) 2026-05-04
LT3820446T (lt) 2021-12-10
HRP20220053T1 (hr) 2022-04-15
MX2021003599A (es) 2021-05-28

Similar Documents

Publication Publication Date Title
IL264210A (en) High-strength oral cannabinoid dosage forms
ZA202102039B (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
EP3621621C0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM
EP3801457B1 (en) STABLE PHARMACEUTICAL COMPOSITIONS FOR PRESSURIZED DOSE-DOSE INHALATORS
PL3297605T3 (pl) Kompozycje farmaceutyczne do stosowania miejscowego
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
IL263516B (en) A dosage form for vaporization and smoking
DK3866767T3 (da) Farmaceutisk sammensætning til oral indgivelse omfattende aminopyrimidinderivat eller salt deraf
PL3661373T3 (pl) Kompozycja farmaceutyczna na niedokrwistość
PL3509573T3 (pl) Kompozycje farmaceutyczne do dostarczania peptydu
EP3868371A4 (en) NOVEL PHARMACEUTICAL COMPOSITION
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
PT3318259T (pt) Composição farmacêutica estável para administração oral
DK3908321T3 (da) Farmaceutisk sammensætning
LT4027973T (lt) Vaistų tiekimo kompozicijos
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
EP3949952A4 (en) MEDICAL COMPOSITION
PT3650024T (pt) Composição farmacêutica para administração nasal compreendendo rifampicinas para tratar demência
IL261929B (en) Stable pharmaceutical preparations for topical administration and their use
PL3845230T3 (pl) Kompozycja farmaceutyczna do podawania doustnego
EP4081251A4 (en) PHARMACEUTICAL COMPOSITIONS
EP4032535A4 (en) PHARMACEUTICAL COMPOSITION
DK2952207T3 (da) Oliebaserede farmaceutiske sammensætninger til oral indgivelse
EP3964264A4 (en) NOVEL PHARMACEUTICAL COMPOSITION
EP3654955C0 (en) PHARMACEUTICAL COMPOSITIONS